Ani Pharmaceuticals (ANIP) Enterprise Value (2016 - 2025)
Ani Pharmaceuticals (ANIP) has disclosed Enterprise Value for 16 consecutive years, with -$285.6 million as the latest value for Q4 2025.
- Quarterly Enterprise Value fell 97.12% to -$285.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$285.6 million through Dec 2025, down 97.12% year-over-year, with the annual reading at -$285.6 million for FY2025, 97.12% down from the prior year.
- Enterprise Value hit -$285.6 million in Q4 2025 for Ani Pharmaceuticals, down from -$262.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$15.3 million in Q3 2021 to a low of -$285.6 million in Q4 2025.
- Historically, Enterprise Value has averaged -$137.6 million across 5 years, with a median of -$145.0 million in 2024.
- Biggest five-year swings in Enterprise Value: plummeted 718.38% in 2021 and later soared 49.45% in 2022.
- Year by year, Enterprise Value stood at -$105.3 million in 2021, then skyrocketed by 49.45% to -$53.2 million in 2022, then crashed by 315.38% to -$221.1 million in 2023, then soared by 34.47% to -$144.9 million in 2024, then plummeted by 97.12% to -$285.6 million in 2025.
- Business Quant data shows Enterprise Value for ANIP at -$285.6 million in Q4 2025, -$262.6 million in Q3 2025, and -$217.8 million in Q2 2025.